Paris (France) (AFP) – A drug called Tavneos, used to treat rare autoimmune diseases, will be pulled from the shelves in France, the country’s medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.
“The recall of all batches available in France will begin on August 19,” France’s medicine safety agency ANSM said in a statement. The agency noted that the European Commission revoked the drug’s marketing authorisation earlier this month because “the benefits are no longer proven to outweigh its risks.”
Tavneos is made by the US biotech firm Amgen and is sold by different partner pharmaceutical companies around the world. It is used to treat adults with severe and rare autoimmune diseases that cause inflammation of the blood vessels. Kissei Pharmaceutical, which sells the drug in Japan, said in May that 20 deaths had been reported among people using it since 2022. The company warned doctors of “the risk of severe liver dysfunction” and asked them to stop prescribing it.
Both Kissei and Amgen stated that the deaths included cases for which no causal link to the medicine could be determined. However, the warning raised doubts about the rigour of the study that was submitted to various regulatory authorities to determine whether it should be authorised for sale. The European Medicines Agency reassessed the data and recommended in July that the drug be stripped of its market authorisation. The European Commission endorsed that recommendation earlier this month.
In France, the drug is prescribed to 600 patients, according to the ANSM. “Abruptly stopping Tavneos without switching to an alternative should be avoided to prevent the condition worsening,” the agency warned, advising patients to consult a doctor about alternatives.
In the United States, the Food and Drug Administration offered Amgen the option of voluntarily withdrawing Tavneos from shelves. However, the company refused, so a procedure is underway to determine whether they will be forced to pull the drug.
© 2024 AFP
